Targeting EGFR/HER2 heterodimerization with a novel anti-HER2 domain II/III antibody.
Yu X, Wang L, Shen Y, Wang C, Zhang Y, Meng Y, Yang Y, Liang B, Zhou B, Wang H, Wei H, Lei C, Hu S, Li B.
Yu X, et al. Among authors: hu s.
Mol Immunol. 2017 Jul;87:300-307. doi: 10.1016/j.molimm.2017.05.010. Epub 2017 May 19.
Mol Immunol. 2017.
PMID: 28531814